In the clinical setting, the administration of two pre-operative doses of a PD-1 inhibitor in patients with resectable non-small cell lung cancer led to an increased number of T-cell clones in the tumour and peripheral blood [25]. The gene discussed is PDCD1; the disease is neoplasm.